Calculators, Algorithms, Drug Interaction CheckersTools
Back To Search Results

Verapamil

Author: Sequoya Fahie Editor: Manouchkathe Cassagnol Updated: 2/6/2023 2:13:16 PM

Indications

The Food and Drug Administration (FDA) Approved Indications for Verapamil are as Follows

  • Angina (chronic stable, vasospastic [prinzmetal variant], unstable angina [cresendo,preinfarction]) 
  • Hypertension (as add on therapy) 
  • Paroxysmal supraventricular tachycardia (PSVT) prophylaxis
  • Supraventricular tachycardia (SVT)

The non-FDA-approved Indications for Verapamil are as Follows

Acute Coronary Syndrome (ACS)

Given as initial treatment in patients with: (1) Non-ST elevation acute coronary syndrome(NSTE-ACS, (2) continuing or frequently recurring ischemia and are unable to use beta-blockers (e.g., contraindication, suffered from unacceptable adverse effects, beta-blockers were insufficient for treatment) in the absence of:

  • Clinically significant LV dysfunction,
  • Increased risk for cardiogenic shock,
  • PR interval greater than 24 seconds, or
  • Second or third-degree AV block without a cardiac pacemaker

Furthermore, long-acting calcium channel blockers and nitrates are recommended in patients with coronary artery spasm (short-acting calcium channel antagonists should be avoided).[1]

Cluster Headaches

Verapamil can be used as a first-line prophylactic at a minimum dosage of 240 mg per day per recommendation to reduce headache severity and decrease the frequency of episodes during a cluster period.[2]

Hypertrophic Cardiomyopathy (HCM)[3]

Recommended for the treatment of symptoms (e.g., angina or dyspnea) in patients with obstructive or non-obstructive HCM who are unable to take beta-blockers (e.g., side effects/contraindications to beta-blockers, unresponsive to beta-blockers).

  • Should be initiated at a low dose and titrated up to 480 mg/day,
  • Its use requires caution in patients with high gradients, advanced heart failure, or sinus bradycardia.

Idiopathic Ventricular Tachycardia (IVT)

There are reports that the chronic use of oral verapamil for verapamil-sensitive idiopathy LVT can control IVT in many patients in both adults and children.[4]

 

Mechanism of Action

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Mechanism of Action

Verapamil is a non-dihydropyridine calcium channel blocker. Calcium channel blockers inhibit the entry of calcium ions into the slow L-type calcium channels in the myocardium and vascular smooth muscle during depolarization. This inhibition will produce relaxation of coronary vascular smooth muscle as well as coronary vasodilation, which is helpful in patients with hypertension. Verapamil also increases myocardial oxygen delivery, which helps patients with vasospastic angina. Verapamil correlates with negative chronotropic effects and decreased sympathetic nervous system activity.[5][6]

 

Administration

Verapamil can be administered either orally (sustained release or immediate release) or intravenously. It is possible to open sustained-release verapamil capsules, and the contents are sprinkled on one tablespoon of applesauce. Patients should receive instructions to swallow immediately with a full glass of cool water. For sustained verapamil products, take with food and swallow whole (they should not be chewed or crushed). When given intravenously, verapamil administration must be over at least a two-minute timeframe. 

Hypertension

  • For immediate-release formulations, the usual dose range is 120 to 360 mg/day given in three divided doses; the maximum dose is 480 mg/day.[7]
  • For geriatric patients, consider lower initial doses and titrate to response.[8]
    • For immediate-release oral formulations, the initial dose is 40 mg three times daily (TID).
    • For extended-release oral formulations, give an initial dose of 120 mg once daily in the morning or 100 mg once daily at bedtime.

Angina

  • For oral dosing, verapamil (immediate-release) should be given 80 mg to 160 mg three times a day (TID).[9]

Atrial Fibrillation (AF)

  • Intravenous[10]
    • Administer an initial bolus of 0.075 to 0.15 mg/kg over at least 2 minutes.
    • If the patient does not produce an adequate response, administer an additional 10 mg after 15 to 30 minutes.
    • If the patient produces an adequate response to the initial (or repeat bolus) dose, initiate a continuous infusion.
  • Oral[11]
    • For extended-release formulations, initiate a maintenance dose of 180 to 480 mg once daily. 
    • For immediate release formulations, initiate a dose of 240 to 480 mg daily in 3 to 4 divided doses; the maximum daily dose should be 480 mg/day.

IVT

  • Intravenous 
    • Administer 2.5 to 5.0 mg every 15 to 30 minutes[12][13]
  • Oral 
    • For immediate-release, formulations administer 360 mg/day in three divided doses.
    • For extended-release formulations, administer 240 to 480 mg once daily.[14][15]

Cluster Headaches

  • Oral: For immediate release formulations, administer 240 mg in three divided doses; if this dose does not produce an adequate response, increase the dose by 80 mg every 1 to 2 weeks until symptoms have alleviated or adverse reactions occur.[16][17]

PSVT Prophylaxis

  • Dosed orally For immediate release formulations, the usual dosage range is between 240 mg and 480 mg in 3 to 4 divided doses.[18]

Ongoing Management of SVT

  • For immediate release formulations, administer an initial dose of 120 mg in divided doses; the maximum maintenance dose is 480 mg/day. 

Acute Treatment of Supraventricular Tachycardia

ACLS Guidelines

  • Administer 2.5 to 5 mg over 2 minutes (over 3 minutes in geriatric patients) administer a second dose of 5 to 10 mg (approximately 0.15 mg/kg) may be given 15 to 30 minutes after the initial dose only if: the patient does not experience any adverse reactions but does not respond to initial treatment.[18]
  • The maximum total dose is 20 to 30 mg.[19]

ACC/AHA/HRS SVT Guidelines

  • Administer 5 to 10 mg (0.075 to 0.15 mg/kg) over 2 minutes
  • If the patient has no response to this dose, a second dose can be given 30 minutes after the initial dose, followed by an infusion of 0.005 mg/kg/minute.
 

Adverse Effects

Adverse Effects

  • Gingival hyperplasia 
  • Constipation 
  • Peripheral edema
  • Hypotension
  • Fatigue
  • Dyspepsia

Precautions

  • May cause first-degree AV block; higher degrees of AV block could occur in patients with sick sinus syndrome - consider a dosage reduction or discontinue verapamil therapy.[19]
  • It is considered contraindicated in patients with wide complex tachycardias unless it can be proven to be supraventricular in origin; severe hypotension could occur upon administration.[20]
  • Avoid use in patients with heart failure, particularly heart failure with a reduced ejection fraction, due to a higher risk than benefit in using calcium channel blockers overall.[21]
  • Use with caution in patients with HCM with outflow tract obstruction, including those:
    • With high gradients
    • Advanced heart failure
    • Sinus bradycardia
    • Verapamil should not be used in those with HCM and systemic hypotension or severe difficulty breathing at rest.[22]

Pregnancy

  • Verapamil can cross the placenta.
  • Pregnancy Category C[23]
  • Use during pregnancy may cause adverse effects on the fetus(e.g., bradycardia, heart block, hypotension)
  •  Women with HCM controlled with verapamil before pregnancy may continue therapy, but it is recommended to monitor the fetus for slow heart rate, low blood pressure, and heart block.[21]
  •  It may be used intravenously for the acute treatment of SVT in pregnant women when adenosine or beta-blockers are ineffective or contraindicated. Verapamil may also be used for the ongoing management of SVT in highly symptomatic patients; the recommendation is for the lowest effective dose; avoid use during the first trimester if possible.[18]
  • If treatment for hypertension during pregnancy is needed, it is recommended to change to an alternative agent. (ACOG 2013)[24]

Breast-Feeding

Although verapamil is present in breast milk, the relative infant dose of verapamil is less than or equal to 1% of the weight-adjusted maternal dose, which is below the required RID limit of less than 10 %.[25][26] Therefore, breastfeeding is acceptable for verapamil, though some manufacturers are against it.[27][28][29][25]  

  • The authors of several case reports calculated the RID of verapamil following maternal use of verapamil 80 to 120 mg three times daily in women less than or equal to 3 months postpartum. Adverse events were not observed in breastfed infants.
 

Contraindications

Oral Formulation

  • If the patient has hypersensitivity to verapamil or any component in the verapamil formulation (immediate-release or extended-release)
  • Severe dysfunction of the left ventricle
  • Severe hypotension, defined as a systolic blood pressure reading of less than 90 mmHg or cardiogenic shock (except in patients with a functioning artificial ventricular pacemaker)
  • Sick sinus syndrome and second or third-degree atrioventricular block (the main exception being in patients who have a functioning artificial ventricular pacemaker)
  • Atrial flutter/fibrillation with an accessory bypass tract (Lown-Ganong-Levine syndrome, Wolff-Parkinson-White [WPW] syndrome)

Intravenous Formulation

  • Severe heart failure (unless the heart failure results from a supraventricular tachycardia responsive to verapamil)
  • Concomitant use of intravenous beta-blockers
 

Monitoring

The clinician should monitor their blood pressure, heart rate, and liver function tests for patients who are on verapamil.

Goals of Therapy

  • Blood pressure is an essential indicator of how the patient with confirmed hypertension is doing with verapamil. The ASCVD risk and comorbidities of the patient require an evaluation to evaluate the specific blood pressure goal for the patient.[30]
  • If the patient with confirmed hypertension has known cardiovascular disease or a 10-year ASCVD risk greater than or equal to 10%, then the recommended target blood pressure is less than 130/80 mm Hg - for patients without markers of increased ASCVD risk, a target blood pressure less than 130/80 is not a recommendation but is a reasonable goal.[30]

Special Populations

  • Renal Impairment: If repeated intravenous injections are necessary for therapy, monitor blood pressure, and PR readings  
  • Liver Impairment (Cirrhosis): Monitor ECG and reduce dose to:
    • 20% in oral formulations
    • 50% in intravenous formulations
 

Toxicity

Like all calcium channel blockers, an overdose of verapamil can lead to negative inotropic and chronotropic effects, dilation of arterial vasculature, and hypotension. Additionally, verapamil’s blockade of slow calcium channels in pancreatic beta cells can lead to inhibited insulin release, thereby causing hyperglycemia. If a patient experiences bradycardia with hypotension/metabolic acidosis and hyperglycemia is indicative of verapamil toxicity. The most serious complications from a verapamil overdose are bradycardia and hypotension, as both can lead to death if the patient is left untreated.

If a patient presents with verapamil toxicity within 1 hour, two decontamination procedures exist; gastric lavage and single-dose activated charcoal.[31][32] If a patient presents with verapamil toxicity after 1 hour of ingestion has elapsed, whole bowel irrigation using polyethylene glycol electrolyte solution is a viable decontamination procedure.[33] According to experimental and clinical studies, ipecac and cathartics have not proven beneficial decontamination procedures.[33][34][35]

Treatment of Calcium Channel Blocker Overdose[36]

Patients with symptoms should undergo treatment with the prioritization of first-line therapy. Determination of which treatment is first-line depends upon the desired effect to include:

  • Intravenous calcium
  • High dose insulin monotherapy (in patients with myocardial dysfunction)
  • Norepinephrine or epinephrine if the patient is suffering from shock (norepinephrine is preferable in patients with vasodilatory shock)

Patients refractory to first-line therapies:

  • Fat emulsion therapies
  • Incremental doses of high dose insulin therapy – in patients with myocardial dysfunction
  • Use of a pacemaker – in patients with unstable bradycardia/high-grade AV block without significant alteration in cardiac inotropy

Patients with refractory shock/precardiac-arrest:   

  • Incremental doses of high dose insulin
  • Fat emulsion therapy
  • Venoarterial extracorporeal membrane oxygenation (only to be used when the refractory shock contains a significant cardiogenic component)

Administration of calcium chloride or calcium gluconate in symptomatic patients is another therapeutic alternative. Calcium chloride is used in nonacidotic patients because it delivers three times the amount of calcium than calcium gluconate. In contrast, calcium gluconate is used in acidotic patients because calcium chloride could worsen the acidosis. Both calcium formulations must have IV administration.  

 

Enhancing Healthcare Team Outcomes

Healthcare professionals (pharmacists, nurses, mid-level practitioners, and doctors) who prescribe and distribute this medication should be aware of the side effects and sound-alike look-alike issues between the verapamil brand names; these concerns require monitoring of heart rate and blood pressure. Pharmacists should educate patients regarding the drug's side effects and how to identify and what to do if they experience them. Further, they should keep track of other medications that the patient is taking to avoid drug-drug interactions. Pharmacists should also educate doctors and nurses on the differences between oral and IV dosing and exercise caution when converting from one route to another. When a clinician decides to switch from oral formulation to intravenous formulation, the total daily dose of verapamil will remain the same unless the strength of the formulation does not allow for direct mg for mg conversion. Therefore, nurses and clinicians should engage the pharmacist when prescribing or counseling on the dosing and administration of the various formulations, and nursing should understand this information for their counseling. This type of interprofessional communication among healthcare team members will improve outcomes using verapamil. [Level 5]

 

References

[1]

Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2014 Dec 23:64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017. Epub 2014 Sep 23     [PubMed PMID: 25260718]

Level 3 (low-level) evidence

[2]

Weaver-Agostoni J. Cluster headache. American family physician. 2013 Jul 15:88(2):122-8     [PubMed PMID: 23939643]

[3]

American College of Cardiology Foundation/American Heart Association Task Force on Practice, American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. The Journal of thoracic and cardiovascular surgery. 2011 Dec:142(6):e153-203. doi: 10.1016/j.jtcvs.2011.10.020. Epub     [PubMed PMID: 22093723]

Level 1 (high-level) evidence

[4]

Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart rhythm. 2018 Oct:15(10):e190-e252. doi: 10.1016/j.hrthm.2017.10.035. Epub 2017 Oct 30     [PubMed PMID: 29097320]

Level 1 (high-level) evidence

[5]

Basile J. The role of existing and newer calcium channel blockers in the treatment of hypertension. Journal of clinical hypertension (Greenwich, Conn.). 2004 Nov:6(11):621-29; quiz 630-1     [PubMed PMID: 15538095]

[6]

Flynn JT, Pasko DA. Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. Pediatric nephrology (Berlin, Germany). 2000 Dec:15(3-4):302-16     [PubMed PMID: 11149130]

[7]

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension (Dallas, Tex. : 1979). 2018 Jun:71(6):e13-e115. doi: 10.1161/HYP.0000000000000065. Epub 2017 Nov 13     [PubMed PMID: 29133356]

Level 3 (low-level) evidence

[8]

Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Forciea MA, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA, ACCF Task Force. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011 May 31:123(21):2434-506. doi: 10.1161/CIR.0b013e31821daaf6. Epub 2011 Apr 25     [PubMed PMID: 21518977]

Level 3 (low-level) evidence

[9]

Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV, American College of Cardiology, American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). Journal of the American College of Cardiology. 2003 Jan 1:41(1):159-68     [PubMed PMID: 12570960]

Level 1 (high-level) evidence

[10]

January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW, ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014 Dec 2:130(23):e199-267. doi: 10.1161/CIR.0000000000000041. Epub 2014 Mar 28     [PubMed PMID: 24682347]

Level 1 (high-level) evidence

[11]

Phillips BG,Gandhi AJ,Sanoski CA,Just VL,Bauman JL, Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter. Pharmacotherapy. 1997 Nov-Dec;     [PubMed PMID: 9399606]

Level 1 (high-level) evidence

[12]

Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018 Sep 25:138(13):e272-e391. doi: 10.1161/CIR.0000000000000549. Epub     [PubMed PMID: 29084731]

[13]

Gill JS, Blaszyk K, Ward DE, Camm AJ. Verapamil for the suppression of idiopathic ventricular tachycardia of left bundle branch block-like morphology. American heart journal. 1993 Nov:126(5):1126-33     [PubMed PMID: 8237755]

[14]

Gill JS, Mehta D, Ward DE, Camm AJ. Efficacy of flecainide, sotalol, and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality. British heart journal. 1992 Oct:68(4):392-7     [PubMed PMID: 1449923]

[15]

Gill JS,Ward DE,Camm AJ, Comparison of verapamil and diltiazem in the suppression of idiopathic ventricular tachycardia. Pacing and clinical electrophysiology : PACE. 1992 Nov;     [PubMed PMID: 1279611]

Level 1 (high-level) evidence

[16]

May A, Leone M, Afra J, Linde M, Sándor PS, Evers S, Goadsby PJ, EFNS Task Force. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. European journal of neurology. 2006 Oct:13(10):1066-77     [PubMed PMID: 16987158]

Level 1 (high-level) evidence

[17]

Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ. Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines. Headache. 2016 Jul:56(7):1093-106. doi: 10.1111/head.12866. Epub     [PubMed PMID: 27432623]

Level 1 (high-level) evidence

[18]

Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ, Estes NAM 3rd, Field ME, Goldberger ZD, Hammill SC, Indik JH, Lindsay BD, Olshansky B, Russo AM, Shen WK, Tracy CM, Al-Khatib SM. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology. 2016 Apr 5:67(13):e27-e115. doi: 10.1016/j.jacc.2015.08.856. Epub 2015 Sep 24     [PubMed PMID: 26409259]

Level 1 (high-level) evidence

[19]

Neumar RW, Otto CW, Link MS, Kronick SL, Shuster M, Callaway CW, Kudenchuk PJ, Ornato JP, McNally B, Silvers SM, Passman RS, White RD, Hess EP, Tang W, Davis D, Sinz E, Morrison LJ. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010 Nov 2:122(18 Suppl 3):S729-67. doi: 10.1161/CIRCULATIONAHA.110.970988. Epub     [PubMed PMID: 20956224]

[20]

WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013 Oct 15:128(16):e240-327. doi: 10.1161/CIR.0b013e31829e8776. Epub 2013 Jun 5     [PubMed PMID: 23741058]

Level 3 (low-level) evidence

[21]

Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011 Dec 13:124(24):e783-831. doi: 10.1161/CIR.0b013e318223e2bd. Epub 2011 Nov 8     [PubMed PMID: 22068434]

Level 1 (high-level) evidence

[22]

Nishimura RA, Holmes DR Jr. Clinical practice. Hypertrophic obstructive cardiomyopathy. The New England journal of medicine. 2004 Mar 25:350(13):1320-7     [PubMed PMID: 15044643]

[23]

Tan HL, Lie KI. Treatment of tachyarrhythmias during pregnancy and lactation. European heart journal. 2001 Mar:22(6):458-64     [PubMed PMID: 11237540]

[24]

Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstetrics and gynecology. 2013 Nov;     [PubMed PMID: 24150027]

[25]

Miller MR, Withers R, Bhamra R, Holt DW. Verapamil and breast-feeding. European journal of clinical pharmacology. 1986:30(1):125-6     [PubMed PMID: 3709626]

[26]

Ito S. Drug therapy for breast-feeding women. The New England journal of medicine. 2000 Jul 13:343(2):118-26     [PubMed PMID: 10891521]

[27]

Andersen HJ. Excretion of verapamil in human milk. European journal of clinical pharmacology. 1983:25(2):279-80     [PubMed PMID: 6628513]

[28]

Anderson P, Bondesson U, Mattiasson I, Johansson BW. Verapamil and norverapamil in plasma and breast milk during breast feeding. European journal of clinical pharmacology. 1987:31(5):625-7     [PubMed PMID: 3830249]

[29]

Inoue H, Unno N, Ou MC, Iwama Y, Sugimoto T. Level of verapamil in human milk. European journal of clinical pharmacology. 1984:26(5):657-8     [PubMed PMID: 6468488]

Level 3 (low-level) evidence

[30]

Aleyadeh W,Hutt-Centeno E,Ahmed HM,Shah NP, Hypertension guidelines: Treat patients, not numbers. Cleveland Clinic journal of medicine. 2019 Jan     [PubMed PMID: 30624184]

[31]

Benson BE, Hoppu K, Troutman WG, Bedry R, Erdman A, Höjer J, Mégarbane B, Thanacoody R, Caravati EM, American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists. Position paper update: gastric lavage for gastrointestinal decontamination. Clinical toxicology (Philadelphia, Pa.). 2013 Mar:51(3):140-6. doi: 10.3109/15563650.2013.770154. Epub 2013 Feb 18     [PubMed PMID: 23418938]

Level 1 (high-level) evidence

[32]

Chyka PA, Seger D, Krenzelok EP, Vale JA, American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists. Position paper: Single-dose activated charcoal. Clinical toxicology (Philadelphia, Pa.). 2005:43(2):61-87     [PubMed PMID: 15822758]

Level 3 (low-level) evidence

[33]

Thanacoody R, Caravati EM, Troutman B, Höjer J, Benson B, Hoppu K, Erdman A, Bedry R, Mégarbane B. Position paper update: whole bowel irrigation for gastrointestinal decontamination of overdose patients. Clinical toxicology (Philadelphia, Pa.). 2015 Jan:53(1):5-12. doi: 10.3109/15563650.2014.989326. Epub 2014 Dec 16     [PubMed PMID: 25511637]

Level 3 (low-level) evidence

[34]

American Academy of Pediatrics Committee on Injury, Violence, and Poison Prevention. Poison treatment in the home. American Academy of Pediatrics Committee on Injury, Violence, and Poison Prevention. Pediatrics. 2003 Nov:112(5):1182-5     [PubMed PMID: 14595067]

Level 1 (high-level) evidence

[35]

Höjer J, Troutman WG, Hoppu K, Erdman A, Benson BE, Mégarbane B, Thanacoody R, Bedry R, Caravati EM, American Academy of Clinical Toxicology, European Association of Poison Centres and Clinical Toxicologists. Position paper update: ipecac syrup for gastrointestinal decontamination. Clinical toxicology (Philadelphia, Pa.). 2013 Mar:51(3):134-9. doi: 10.3109/15563650.2013.770153. Epub 2013 Feb 13     [PubMed PMID: 23406298]

Level 1 (high-level) evidence

[36]

St-Onge M, Anseeuw K, Cantrell FL, Gilchrist IC, Hantson P, Bailey B, Lavergne V, Gosselin S, Kerns W 2nd, Laliberté M, Lavonas EJ, Juurlink DN, Muscedere J, Yang CC, Sinuff T, Rieder M, Mégarbane B. Experts Consensus Recommendations for the Management of Calcium Channel Blocker Poisoning in Adults. Critical care medicine. 2017 Mar:45(3):e306-e315. doi: 10.1097/CCM.0000000000002087. Epub     [PubMed PMID: 27749343]

Level 3 (low-level) evidence